

February 15, 2026

## Q3FY26 Result Update

☑ Change in Estimates | ☑ Target | ☑ Reco

### Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	BUY		ACCUMULATE	
Target Price	4,750		4,200	
Sales (Rs. m)	1,47,463	1,65,330	1,45,058	1,62,294
% Chng.	1.7	1.9		
EBITDA (Rs. m)	49,489	57,244	49,352	56,772
% Chng.	0.3	0.8		
EPS (Rs.)	91.7	112.0	91.8	111.7
% Chng.	-	0.2		

### Key Financials - Consolidated

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. m)	1,15,160	1,31,231	1,47,463	1,65,330
EBITDA (Rs. m)	37,210	43,159	49,489	57,244
Margin (%)	32.3	32.9	33.6	34.6
PAT (Rs. m)	19,110	24,632	31,011	37,849
EPS (Rs.)	57.2	72.9	91.7	112.0
Gr. (%)	23.4	27.3	25.9	22.0
DPS (Rs.)	32.0	30.0	40.0	40.0
Yield (%)	0.8	0.7	1.0	1.0
RoE (%)	26.8	29.9	32.2	32.9
RoCE (%)	27.3	33.3	38.2	40.6
EV/Sales (x)	12.2	10.6	9.3	8.2
EV/EBITDA (x)	37.7	32.2	27.8	23.6
PE (x)	71.2	56.0	44.4	36.4
P/BV (x)	18.2	15.5	13.3	10.9

### Key Data

TORP.BO | TRP IN

52-W High / Low	Rs.4,240 / Rs.2,886
Sensex / Nifty	82,627 / 25,471
Market Cap	Rs.1,380bn/ \$ 15,226m
Shares Outstanding	338m
3M Avg. Daily Value	Rs.920.32m

### Shareholding Pattern (%)

Promoter's	68.31
Foreign	15.92
Domestic Institution	9.17
Public & Others	6.60
Promoter Pledge (Rs bn)	-

### Stock Performance (%)

	1M	6M	12M
Absolute	3.5	12.7	32.7
Relative	4.7	9.9	22.2

### Param Desai

paramdesai@plindia.com | 91-22-66322259

### Kushal Shah

kushalshah@plindia.com | 91-22-66322490

## Strong quarter; guides Rs4-4.5bn cost synergies

### Quick Pointers:

- Net debt/ EBITDA to be 1.1x by FY27E and 0.6x by FY28E post JBCP merger.
- Guided cost synergies of Rs 4-4.5bn from JBCP merger over the next 3 years.

**Torrent Pharma's (TRP) reported strong quarter with Q3FY26 EBITDA of 19% YoY. TRP reported Rs 100bn (80% of total sales) worth of highly profitable branded formulation (BGx) sales spread across India, Brazil and RoW markets. The acquisition of JB Chemicals & Pharma (JBCP) appears strategically compelling, making it the 5th largest player in the domestic pharma market. This will further be strengthening its position in high-margin chronic therapies and opens up many newer therapeutic areas. The deal also adds JBCP's CDMO vertical, offering diversification and growth optionality.**

**The cost synergies guidance of Rs4-4.5bn deal is positive and expect combined entity EBITDA to be at Rs77-78bn in FY28. TRP trades at 26x and 22x EV/EBITDA on FY27E and FY28E for the combined business. We upgrade stock to "BUY" from "Accumulate" with revised TP of Rs4,750/share, valuing at 25x EV/EBITDA on FY28E for combined entity.**

- Domestic and RoW markets aid growth YoY:** Revenues grew by 18% YoY to Rs 33bn, vs our estimates of Rs32.4bn. Domestic business grew by 14% YoY. US sales declined 7% QoQ to \$36mn. Brazil market was up 27% YoY. CC growth was strong at 10% YoY. Top brands and new launches supported growth. Germany delivered growth of 8% YoY to Rs 3bn. CC growth was down by 6% impacted due to certain supply disruption. RoW including CRAMS growth was healthy at 33% YoY.
- Healthy EBITDA growth:** GM remained steady at 75.4% flat YoY. TRP reported EBITDA of Rs 10.9bn (up 19% YoY), vs our estimate of Rs 10.5bn. Other income came in negative to the tune of Rs 130mn led by forex loss of Rs450mn. Other expenses were up 14% YoY. Tax rate was lower. PAT stood at Rs 6.3bn (up 26% YoY); Adj for forex PAT was above our estimates.

### Key concall takeaways:

- India:** Growth drivers: Volume 5.5%, Price 5.8%, New products 2.7%. The company continued to outperform in chronic and sub-chronic therapies, particularly in cardiac, gastro, and diabetes segments. Field force expanded to 6,900 reps (vs 6,800 in Q1); target 7,000 by FY26E and further to 7500 by FY27E.
- Curatio** continues to outperform; +27% YoY in Q3, aided by increased OTC advertising spends, expansion of the field force and improved demand generation initiatives.

- **Brazil:** Growth led by healthy volume expansion and mid-single-digit price increases. However, price growth has moderated due to controlled inflation and intense competition with price hikes limited to 4-5%. Expect 10-15% growth with 5-6 annual launches. Torrent has 60 products pending approval with ANVISA.
- **Semaglutide:** Mgmt expects to be in 3/4<sup>th</sup> wave of launch in Brazil. Oral semaglutide is being evaluated in Brazil markets.
- **Germany:** Supply disruption at third-party supplier which impacted sales; visibility remains unclear. TRP is onboarding alternate suppliers over the next 3-4 quarters and shifting select products to its own facilities.
- **US markets:** Growth supported by new launches and increased volumes on existing contracts. Expect 5-7 product launches annually. Targets \$200mn in revenues.
- **JBCP Acquisition:** Mgmt expects cost synergies of Rs 4-4.5bn over 2-3years. The synergy guidance excludes potential benefits from the Novartis ophthalmology portfolio and the Azmarda portfolio. This cost synergies will reflect 20% in year 1, 60% in year 2 and remaining 20% in year 3. The JBCP's trade generics business, currently at near-zero margins, is under strategic review and may be rationalized or merged with TRP base trade generics operations. MR Attrition levels have remained stable following the acquisition announcement. Expect merger to be completed post 6-9 months post NCLT filing shortly
- **Other: Capex:** Net debt stood at Rs 8.8bn as of Q3FY26. Post JBCP acquisition, net debt to EBITDA is expected to be at ~1.1x by FY28 and ~0.6x by FY29. Average interest cost is approximately 7.6%.

**Exhibit 1: Q3FY26 Result Overview (Rs mn): EBITDA in line, BGx aids growth YoY**

Y/e March	Q3FY26	Q3FY25	YoY gr. (%)	Q3FY26E	% Var	Q2FY26	QoQ gr. (%)	9M FY26	9M FY25	YoY gr. (%)
<b>Net Sales</b>	<b>33,030</b>	<b>28,090</b>	<b>17.6</b>	<b>32,439</b>	<b>1.8</b>	<b>33,020</b>	<b>0.0</b>	<b>97830</b>	<b>85,570</b>	<b>14.3</b>
Raw Material	7,990	6,730	18.7	7,810	2.3	8,000	(0.1)	23,730	20,450	16.0
<i>% of Net Sales</i>	<i>24.2</i>	<i>24.0</i>		<i>24.1</i>		<i>24.2</i>		<i>24.3</i>	<i>23.9</i>	
Personnel Cost	6,510	5,490	18.6	6,250	4.2	6,270	3.8	18830	16,420	14.7
<i>% of Net Sales</i>	<i>19.7</i>	<i>19.5</i>		<i>19.3</i>		<i>19.0</i>		<i>19.2</i>	<i>19.2</i>	
Others	7,650	6,730	13.7	7,800	(1.9)	7,920	(3.4)	23,240	21,130	10.0
<i>% of Net Sales</i>	<i>23.2</i>	<i>24.0</i>		<i>24.0</i>		<i>24.0</i>		<i>23.8</i>	<i>24.7</i>	
Total Expenditure	22,150	18,950	16.9	21,860	1.3	22,190	(0.2)	65,800	58,000	13.4
<b>EBITDA</b>	<b>10,880</b>	<b>9,140</b>	<b>19.0</b>	<b>10,579</b>	<b>2.8</b>	<b>10,830</b>	<b>0.5</b>	<b>32,030</b>	<b>27,570</b>	<b>16.2</b>
<i>Margin (%)</i>	<i>32.9</i>	<i>32.5</i>		<i>32.6</i>		<i>32.8</i>		<i>32.7</i>	<i>32.2</i>	
Depreciation	2,060	1,990	3.5	2,020	2.0	2,040	1.0	6110	5,940	2.9
<b>EBIT</b>	<b>8,820</b>	<b>7,150</b>	<b>23.4</b>	<b>8,559</b>	<b>3.0</b>	<b>8,790</b>	<b>0.3</b>	<b>25,920</b>	<b>21,630</b>	<b>19.8</b>
Other Income	(130)	330	(139.4)	200	(165.0)	(270)	(51.9)	-770	410	(287.8)
Interest	450	570	(21.1)	470	(4.3)	480	(6.3)	1490	1,960	(24.0)
<b>PBT</b>	<b>8,240</b>	<b>6,910</b>	<b>19.2</b>	<b>8,289</b>	<b>(0.6)</b>	<b>8,040</b>	<b>2.5</b>	<b>23,660</b>	<b>20,080</b>	<b>17.8</b>
Total Taxes	1,790	1,880	(4.8)	2,189	(18.2)	2,000	(10.5)	5690	5,950	(4.4)
<i>ETR (%)</i>	<i>21.7</i>	<i>27.2</i>		<i>26.4</i>		<i>24.9</i>		<i>24.0</i>	<i>29.6</i>	
Minority Interest	-	-	-	-	-	-	-	-	-	-
<b>Reported PAT</b>	<b>6,450</b>	<b>5,030</b>	<b>28.2</b>	<b>6,100</b>	<b>5.7</b>	<b>6,040</b>	<b>6.8</b>	<b>17,970</b>	<b>14,130</b>	<b>27.2</b>
Extra-Ord. Inc./Exps.	-	-	-	-	-	-	-	-	-	-
<b>Adjusted PAT</b>	<b>6,450</b>	<b>5,030</b>	<b>28.2</b>	<b>6,100</b>	<b>5.7</b>	<b>6,040</b>	<b>6.8</b>	<b>17,970</b>	<b>14,130</b>	<b>27.2</b>


Source: Company, PL

**Exhibit 2: Sources of Revenue – Healthy growth from branded generics**

Y/e March	Q3FY26	Q3FY25	YoY gr. (%)	Q2FY26	QoQ gr. (%)	9M FY26	9M FY25	YoY gr. (%)
<b>Domestic Sales</b>	<b>17,980</b>	<b>15,810</b>	<b>13.7</b>	<b>18,200</b>	<b>(1.2)</b>	<b>54,290</b>	<b>48,480</b>	<b>12.0</b>
Branded Business	17,980	15,810	13.7	18,200	(1.2)	54290	48,480	12.0
<i>% of sales</i>	<i>54.4</i>	<i>56.3</i>		<i>55.1</i>		<i>63.4</i>	<i>56.7</i>	
<b>Exports</b>	<b>15,050</b>	<b>12,280</b>	<b>22.6</b>	<b>14,820</b>	<b>1.6</b>	<b>43,540</b>	<b>37,090</b>	<b>17.4</b>
<i>% of sales</i>	<i>45.6</i>	<i>43.7</i>		<i>44.9</i>		<i>50.9</i>	<i>43.3</i>	
Brazil	3,710	2,910	27.5	3,180	16.7	9070	7,500	20.9
<i>% of sales</i>	<i>11.2</i>	<i>10.4</i>		<i>9.6</i>		<i>10.6</i>	<i>8.8</i>	
USA	3,210	2,710	18.5	3,370	(4.7)	9660	7,980	21.1
<i>% of sales</i>	<i>9.7</i>	<i>9.6</i>		<i>10.2</i>		<i>11.3</i>	<i>9.3</i>	
Germany	3,040	2,820	7.8	3,030	0.3	9150	8,540	7.1
<i>% of sales</i>	<i>9.2</i>	<i>10.0</i>		<i>9.2</i>		<i>10.7</i>	<i>10.0</i>	
Others	5,090	3,840	32.6	5,240	(2.9)	15660	13,070	19.8
<i>% of sales</i>	<i>15.4</i>	<i>13.7</i>		<i>15.9</i>		<i>18.3</i>	<i>15.3</i>	
<b>Total Sales</b>	<b>33,030</b>	<b>28,090</b>	<b>17.6</b>	<b>33,020</b>	<b>0.0</b>	<b>97,830</b>	<b>85,570</b>	<b>14.3</b>


Source: Company, PL

**Exhibit 3: Chronic business remained healthy YoY**




Source: Company, PL

**Exhibit 4: Higher growth from RoW markets**




Source: Company, PL

**Exhibit 5: Sustainable margins**



Source: Company, PL

**Exhibit 6: R&D spend maintained at current levels**



Source: Company, PL

## Financials

### Income Statement (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
<b>Net Revenues</b>	<b>1,15,160</b>	<b>1,31,231</b>	<b>1,47,463</b>	<b>1,65,330</b>
YoY gr. (%)	7.3	14.0	12.4	12.1
Cost of Goods Sold	27,760	31,766	35,614	39,175
Gross Profit	87,400	99,465	1,11,849	1,26,155
Margin (%)	75.9	75.8	75.8	76.3
Employee Cost	22,030	25,335	28,375	31,780
Other Expenses	14,237	15,795	17,443	19,266
<b>EBITDA</b>	<b>37,210</b>	<b>43,159</b>	<b>49,489</b>	<b>57,244</b>
YoY gr. (%)	10.5	16.0	14.7	15.7
Margin (%)	32.3	32.9	33.6	34.6
Depreciation and Amortization	7,950	8,189	8,270	8,353
<b>EBIT</b>	<b>29,260</b>	<b>34,970</b>	<b>41,219</b>	<b>48,891</b>
Margin (%)	25.4	26.6	28.0	29.6
Net Interest	2,520	1,908	826	292
Other Income	230	(653)	956	2,205
<b>Profit Before Tax</b>	<b>26,970</b>	<b>32,410</b>	<b>41,349</b>	<b>50,804</b>
Margin (%)	23.4	24.7	28.0	30.7
Total Tax	7,620	7,778	10,337	12,955
Effective tax rate (%)	28.3	24.0	25.0	25.5
<b>Profit after tax</b>	<b>19,350</b>	<b>24,632</b>	<b>31,011</b>	<b>37,849</b>
Minority interest	-	-	-	-
Share Profit from Associate	-	-	-	-
<b>Adjusted PAT</b>	<b>19,110</b>	<b>24,632</b>	<b>31,011</b>	<b>37,849</b>
YoY gr. (%)	15.4	28.9	25.9	22.0
Margin (%)	16.6	18.8	21.0	22.9
Extra Ord. Income / (Exp)	240	-	-	-
<b>Reported PAT</b>	<b>19,350</b>	<b>24,632</b>	<b>31,011</b>	<b>37,849</b>
YoY gr. (%)	23.4	27.3	25.9	22.0
Margin (%)	16.8	18.8	21.0	22.9
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	19,350	24,632	31,011	37,849
<b>Equity Shares O/s (m)</b>	<b>338</b>	<b>338</b>	<b>338</b>	<b>338</b>
<b>EPS (Rs)</b>	<b>57.2</b>	<b>72.9</b>	<b>91.7</b>	<b>112.0</b>

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs m)

Y/e Mar	FY25	FY26E	FY27E	FY28E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>1,40,261</b>	<b>1,44,261</b>	<b>1,49,261</b>	<b>1,54,261</b>
Tangibles	54,702	56,262	58,212	60,162
Intangibles	85,559	87,999	91,049	94,099
<b>Acc: Dep / Amortization</b>	<b>64,191</b>	<b>72,379</b>	<b>80,649</b>	<b>89,003</b>
Tangibles	64,191	72,379	80,649	89,003
Intangibles	-	-	-	-
<b>Net fixed assets</b>	<b>76,070</b>	<b>71,882</b>	<b>68,611</b>	<b>65,258</b>
Tangibles	(9,489)	(16,117)	(22,438)	(28,841)
Intangibles	85,559	87,999	91,049	94,099
Capital Work In Progress	8,170	8,170	8,170	8,170
Goodwill	-	-	-	-
Non-Current Investments	440	440	440	440
Net Deferred tax assets	(2,340)	(2,340)	(2,340)	(2,340)
Other Non-Current Assets	-	-	-	-
<b>Current Assets</b>				
Investments	1,120	1,120	1,120	1,120
Inventories	25,410	28,696	32,303	36,273
Trade receivables	18,670	21,522	24,227	27,205
Cash & Bank Balance	5,790	4,521	11,946	27,568
Other Current Assets	8,200	8,610	9,041	9,493
<b>Total Assets</b>	<b>1,43,950</b>	<b>1,45,040</b>	<b>1,55,938</b>	<b>1,75,607</b>
<b>Equity</b>				
Equity Share Capital	1,690	1,690	1,690	1,690
Other Equity	74,220	86,988	1,02,181	1,24,212
<b>Total Networth</b>	<b>75,910</b>	<b>88,678</b>	<b>1,03,871</b>	<b>1,25,902</b>
<b>Non-Current Liabilities</b>				
Long Term borrowings	11,920	8,920	5,920	2,920
Provisions	-	-	-	-
Other non current liabilities	-	-	-	-
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	18,340	6,340	2,340	-
Trade payables	18,200	21,522	24,227	27,205
Other current liabilities	17,240	17,240	17,240	17,240
<b>Total Equity &amp; Liabilities</b>	<b>1,43,950</b>	<b>1,45,040</b>	<b>1,55,938</b>	<b>1,75,607</b>

Source: Company Data, PL Research

**Cash Flow (Rs m)**

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	26,740	33,063	40,393	48,599
Add. Depreciation	7,950	8,189	8,270	8,353
Add. Interest	2,520	1,908	826	292
Less Financial Other Income	230	(653)	956	2,205
Add. Other	-	-	-	-
Op. profit before WC changes	37,210	43,159	49,489	57,244
Net Changes-WC	(4,810)	(3,226)	(4,038)	(4,423)
Direct tax	(6,030)	(7,778)	(10,337)	(12,955)
<b>Net cash from Op. activities</b>	<b>26,370</b>	<b>32,155</b>	<b>35,115</b>	<b>39,866</b>
Capital expenditures	(6,290)	(4,000)	(5,000)	(5,000)
Interest / Dividend Income	-	-	-	-
Others	-	-	-	-
<b>Net Cash from Inv. activities</b>	<b>(6,290)</b>	<b>(4,000)</b>	<b>(5,000)</b>	<b>(5,000)</b>
Issue of share cap. / premium	-	-	-	-
Debt changes	(9,260)	(15,000)	(7,000)	(5,340)
Dividend paid	(10,830)	(11,864)	(15,818)	(15,818)
Interest paid	(2,520)	(1,908)	(826)	(292)
Others	(70)	(653)	956	2,205
<b>Net cash from Fin. activities</b>	<b>(22,680)</b>	<b>(29,424)</b>	<b>(22,689)</b>	<b>(19,245)</b>
<b>Net change in cash</b>	<b>(2,600)</b>	<b>(1,269)</b>	<b>7,426</b>	<b>15,621</b>
Free Cash Flow	20,260	28,155	30,115	34,866

Source: Company Data, PL Research

**Quarterly Financials (Rs m)**

Y/e Mar	Q4FY25	Q1FY26	Q2FY26	Q3FY26
<b>Net Revenue</b>	<b>29,590</b>	<b>31,780</b>	<b>33,020</b>	<b>33,030</b>
YoY gr. (%)	7.8	11.2	14.3	17.6
Raw Material Expenses	7,310	7,740	8,000	7,990
Gross Profit	22,280	24,040	25,020	25,040
Margin (%)	75.3	75.6	75.8	75.8
<b>EBITDA</b>	<b>9,640</b>	<b>10,320</b>	<b>10,830</b>	<b>10,880</b>
YoY gr. (%)	9.2	14.2	15.3	19.0
Margin (%)	32.6	32.5	32.8	32.9
Depreciation / Depletion	2,010	2,010	2,040	2,060
<b>EBIT</b>	<b>7,630</b>	<b>8,310</b>	<b>8,790</b>	<b>8,820</b>
Margin (%)	25.8	26.1	26.6	26.7
Net Interest	560	560	480	450
Other Income	(180)	(370)	(270)	(130)
<b>Profit before Tax</b>	<b>6,890</b>	<b>7,380</b>	<b>8,040</b>	<b>8,240</b>
Margin (%)	23.3	23.2	24.3	24.9
Total Tax	1,670	1,900	2,000	1,790
Effective tax rate (%)	24.2	25.7	24.9	21.7
<b>Profit after Tax</b>	<b>5,220</b>	<b>5,480</b>	<b>6,040</b>	<b>6,450</b>
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
<b>Adjusted PAT</b>	<b>4,980</b>	<b>5,480</b>	<b>6,040</b>	<b>6,450</b>
YoY gr. (%)	10.9	19.9	33.3	28.2
Margin (%)	16.8	17.2	18.3	19.5
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>4,980</b>	<b>5,480</b>	<b>6,040</b>	<b>6,450</b>
YoY gr. (%)	10.9	19.9	33.3	28.2
Margin (%)	16.8	17.2	18.3	19.5
Other Comprehensive Income	-	-	-	-
<b>Total Comprehensive Income</b>	<b>4,980</b>	<b>5,480</b>	<b>6,040</b>	<b>6,450</b>
Avg. Shares O/s (m)	338	338	338	338
<b>EPS (Rs)</b>	<b>15.4</b>	<b>16.2</b>	<b>17.5</b>	<b>18.8</b>

Source: Company Data, PL Research

**Key Financial Metrics**

Y/e Mar	FY25	FY26E	FY27E	FY28E
<b>Per Share(Rs)</b>				
EPS	57.2	72.9	91.7	112.0
CEPS	80.1	97.1	116.2	136.7
BVPS	224.6	262.4	307.3	372.5
FCF	59.9	83.3	89.1	103.2
DPS	32.0	30.0	40.0	40.0
<b>Return Ratio(%)</b>				
RoCE	27.3	33.3	38.2	40.6
ROIC	21.4	25.1	28.9	33.3
RoE	26.8	29.9	32.2	32.9
<b>Balance Sheet</b>				
Net Debt : Equity (x)	0.3	0.1	0.0	(0.2)
Net Working Capital (Days)	82	80	80	80
<b>Valuation(x)</b>				
PER	71.2	56.0	44.4	36.4
P/B	18.2	15.5	13.3	10.9
P/CEPS	50.9	42.0	35.1	29.8
EV/EBITDA	37.7	32.2	27.8	23.6
EV/Sales	12.2	10.6	9.3	8.2
Dividend Yield (%)	0.8	0.7	1.0	1.0


Source: Company Data, PL Research

**Key Operating Metrics**

Y/e Mar	FY25	FY26E	FY27E	FY28E
Domestic	63,930	71,871	80,496	90,155
Export	48,230	55,910	63,241	71,151
Contract Manufacturing	3,000	3,450	3,726	4,024

Source: Company Data, PL Research

**Price Chart**



**Recommendation History**

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	08-Jan-26	Accumulate	4,200	4,092
2	10-Nov-25	Accumulate	4,200	3,580
3	08-Oct-25	Accumulate	4,000	3,539
4	29-Jul-25	Accumulate	4,000	3,623
5	08-Jul-25	Accumulate	3,850	3,354
6	01-Jul-25	Accumulate	3,850	3,408
7	21-May-25	Accumulate	3,670	3,233
8	08-Apr-25	Accumulate	3,750	3,234

**Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Ajanta Pharma	BUY	3,200	2,768
2	Apollo Hospitals Enterprise	BUY	9,000	7,507
3	Aster DM Healthcare	BUY	715	558
4	Aurobindo Pharma	BUY	1,300	1,124
5	Brigade Enterprises	BUY	1,045	843
6	Cipla	Accumulate	1,440	1,315
7	Divi's Laboratories	Accumulate	6,850	6,387
8	Dr. Reddy's Laboratories	Reduce	1,300	1,157
9	Eris Lifesciences	BUY	1,900	1,553
10	Fortis Healthcare	BUY	1,120	915
11	Global Health	BUY	1,375	1,108
12	HealthCare Global Enterprises	BUY	850	586
13	Indoco Remedies	Hold	325	225
14	Ipca Laboratories	BUY	1,600	1,514
15	J.B. Chemicals & Pharmaceuticals	BUY	2,300	1,927
16	Jupiter Life Line Hospitals	BUY	1,600	1,251
17	Krishna Institute of Medical Sciences	BUY	810	647
18	Lupin	BUY	2,400	2,214
19	Max Healthcare Institute	BUY	1,300	1,040
20	Narayana Hrudayalaya	BUY	2,100	1,901
21	Oberoi Realty	Accumulate	1,820	1,647
22	Prestige Estates Projects	BUY	1,880	1,500
23	Rainbow Children's Medicare	BUY	1,550	1,179
24	Sun Pharmaceutical Industries	BUY	1,900	1,595
25	Sunteck Realty	BUY	550	374
26	Torrent Pharmaceuticals	Accumulate	4,200	4,092
27	Zydus Lifesciences	Accumulate	1,020	887

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (UR)</b>	: Rating likely to change shortly



## **ANALYST CERTIFICATION**

### **(Indian Clients)**

We/I, Mr. Param Desai- MBA Finance, Mr. Kushal Shah- CFP, Passed CFA Level I Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### **(US Clients)**

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai- MBA Finance, Mr. Kushal Shah- CFP, Passed CFA Level I Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

**Prabhudas Lilladher Pvt. Ltd.**

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

[www.plindia.com](http://www.plindia.com)